Peptide Compounds

A pentadecapeptide (15 amino acids) derived from human gastric juice. Research suggests it may support tissue repair mechanisms including tendons, ligaments, muscles, and the gastrointestinal tract.

A synthetic version of a naturally occurring 43-amino acid peptide present in virtually all human and animal cells. Research focuses on its role in cell migration, blood vessel formation, and tissue repair.

A non-erythropoietic peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR). Retains tissue-protective and anti-inflammatory properties without stimulating red blood cell production.

A naturally occurring copper tripeptide found in human plasma. Research explores its role in wound healing, collagen synthesis, and anti-inflammatory activity.

A synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. Studied for its effects on melanogenesis, sexual function, and appetite suppression.

A mitochondria-targeting tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Research investigates its cardioprotective and neuroprotective effects.

A critical coenzyme found in every living cell, essential for energy metabolism, DNA repair, and cellular signaling. Levels decline with age.

A synthetic tetrapeptide based on the natural pineal gland peptide epithalamin. Studied for its potential effects on telomere length and cellular aging.

An enhanced acetylated form of Semax, a synthetic heptapeptide analog of ACTH. Research explores nootropic and neuroprotective effects.

An enhanced form of Selank, a synthetic heptapeptide analog of the natural tetrapeptide tuftsin. Studied for anxiolytic and cognitive-enhancing properties.

A nonapeptide with roles in sleep regulation, stress response, and circadian rhythm modulation. Studied for its potential in sleep disorder management.

A synthetic analog of growth hormone-releasing hormone (GHRH) with an extended half-life due to Drug Affinity Complex (DAC) modification. Stimulates sustained GH and IGF-1 secretion.

A selective growth hormone secretagogue and ghrelin receptor agonist. Offers pulsatile GH release with minimal effect on cortisol or prolactin levels.

A synthetic GHRH analog approved by the FDA for HIV-associated lipodystrophy. Studied for its effects on visceral fat reduction and body composition.

A synthetic analog of the first 29 amino acids of GHRH. Stimulates the pituitary gland to produce and secrete natural growth hormone.

A modified form of IGF-1 with a longer half-life than native IGF-1. Studied for its anabolic effects on muscle tissue and cellular growth.

A naturally occurring peptide derived from thymosin fraction 5. Studied extensively for immune modulation, antiviral activity, and its role in regulatory T cell function.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and obesity management. The only peptide with broad FDA approval for therapeutic use.

A modified fragment of human growth hormone (hGH176-191) studied for its potential fat-burning properties without the growth-promoting effects of full hGH.

A 28-amino acid neuropeptide with potent vasodilatory and immunomodulatory effects. Studied for its role in inflammatory conditions and CIRS treatment protocols.

A synthetic analog of alpha-MSH. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Acts centrally through melanocortin receptors.

A tripeptide derived from the C-terminus of alpha-MSH. Studied for potent anti-inflammatory effects, particularly in inflammatory bowel conditions.

Synergistic blend targeting multiple tissue repair pathways simultaneously. BPC-157 provides local repair signals while TB-500 promotes systemic cell migration and angiogenesis.

A complementary GH-stimulating blend combining sustained GHRH signaling (CJC-1295) with pulsatile ghrelin receptor activation (Ipamorelin) for physiologic GH release patterns.